Smartleaf Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Smartleaf Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-228	Closed	-$30.1K	–	3011
2025 Q1	$30.1K	Sell	228 -7	-3%	-$872	﹤0.01%	1405
2024 Q4	$19.6K	Buy	235 +51	+28%	+$4.19K	﹤0.01%	1656
2024 Q3	$13.5K	Buy	184 +83	+82%	+$6.24K	﹤0.01%	1575
2024 Q2	$7.17K	Buy	+101	New	+$7K	﹤0.01%	1601

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Smartleaf Asset Management's ITCI Position: Q2 2025 in Review

Smartleaf Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 228 shares — an estimated $30.1K sold.

Smartleaf Asset Management first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $30.1K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Smartleaf Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Smartleaf Asset Management sold 228 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $30.1K.
Smartleaf Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
Smartleaf Asset Management's Intra-Cellular Therapies Inc. position peaked at $30.1K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Smartleaf Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.